{
  "id": "6020ab801cb411341a000081",
  "type": "yesno",
  "question": "Is belimumab effective for the lupus nephritis?",
  "ideal_answer": "Yes, belimumab appears to effective for the lupus nephritis.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/24014569",
    "http://www.ncbi.nlm.nih.gov/pubmed/32537456",
    "http://www.ncbi.nlm.nih.gov/pubmed/25969652",
    "http://www.ncbi.nlm.nih.gov/pubmed/33186226",
    "http://www.ncbi.nlm.nih.gov/pubmed/32755035",
    "http://www.ncbi.nlm.nih.gov/pubmed/32591783",
    "http://www.ncbi.nlm.nih.gov/pubmed/29514612",
    "http://www.ncbi.nlm.nih.gov/pubmed/26712500",
    "http://www.ncbi.nlm.nih.gov/pubmed/32937045"
  ],
  "snippets": [
    {
      "text": "Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32591783",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSIONS: Combined B-cell targeted therapy with RTX and BLM prevented full B-cell repopulation including DN B cells, with concomitant specific reduction of SLE-relevant autoantibodies. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32591783",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Clinical Efficacy of Routinely Administered Belimumab on Proteinuria and Neuropsychiatric Lupus.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32537456",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Conclusions: In our series, BEL led to a decrease of proteinuria in patients with proteinuria of more than 1,000 mg/g creatinine despite standard of care treatment, and led to a marked clinical improvement in one patient with NPSLE. No adverse events were observed. Routinely administered BEL shows clinical efficacy on non-approved manifestations, but careful patient selection is warranted.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32537456",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32755035",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "OBJECTIVE: To assess the safety, mechanism of action, and preliminary efficacy of rituximab followed by belimumab in the treatment of refractory lupus nephritis (LN).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32755035",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION: The addition of belimumab to a treatment regimen with rituximab and CYC was safe in patients with refractory LN.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32755035",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RECENT FINDINGS: Recently, the Belimumab in Subjects with Systemic Lupus Erythematosus - Lupus Nephritis trial tested belimumab, an inhibitor of B-cell activating factor, as an add-on therapy to steroids and either mycophenolate mofetil (MMF) or cyclophosphamide when given IV monthly over a period of 104 weeks at an effect size of 11% for a Primary Efficacy Renal Response. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33186226",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Case report: successful treatment of membranous lupus nephritis with belimumab in an African female immigrant.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26712500",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Recently introduced into the market, belimumab (Benlysta) is a monoclonal antibody that has potential clinically efficacious applications for the treatment of lupus nephritis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25969652",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Successful treatment of a mycophenolate mofetil-refractory proliferative lupus nephritis with Belimumab in a 19-year-old woman.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014569",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Following treatment with belimumab, proteinuria rapidly improved to almost normal levels and clinical remission lasted. Belimumab might hold promise for this indication.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014569",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}